Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland
Karolina Hoffmann,1 Michał Michalak,2 Anna Paczkowska3 1Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Poznań, Poland; 2Department of Computer Science and Statistics, Poznan University of Medical Sciences, Pozn...
Saved in:
| Main Authors: | Hoffmann K, Michalak M, Paczkowska A |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-08-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/relative-effectiveness-and-safety-of-the-glp-1-glucagon-like-peptide-1-peer-reviewed-fulltext-article-DMSO |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study
by: Anders Boisen Jensen, et al.
Published: (2025-04-01) -
Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01) -
Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review
by: Juliana West, et al.
Published: (2025-04-01) -
Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
by: Łukasz Zdziebkowski, et al.
Published: (2025-07-01) -
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
by: Rui Salvador, et al.
Published: (2025-03-01)